Summary
Recorded Future's Insikt Group published its "Emerging Threats to Neurotechnology" report on August 6, 2026, with media coverage appearing in early September 2026. The report formally classifies neurological, biometric, and behavioral data collected by brain-computer interfaces (BCIs) and consumer neurotechnology devices as an emerging target for cybercriminals and state-linked threat actors [1][2]. The report arrives as the global neurotechnology market is projected to reach $53 billion by 2034 [2], the BCI sector reportedly closed Q1 2026 with over $960 million raised [6], and consumer-facing neural devices from companies like Neurable are reportedly already commercially available [6].
No confirmed cyberattack on a clinical BCI implant has been publicly reported as of 2026 [11]. The threat is anticipatory, not realized in the wild. But three converging factors make this worth tracking now: rapid commercial expansion of neural data collection, strategic competition between the United States and China over neurotechnology dominance, and a fragmented regulatory environment that does not yet address the technology's data collection capabilities.
Four Threat Categories From the Insikt Group Report
Insikt Group structures the threat picture around four categories [1][2]:
State-sponsored espionage and intellectual property theft. Neurotechnology R&D is expensive and strategically valuable. The report predicts that leading neurotechnology companies will face increased targeting for intellectual property, with state-sponsored attackers and malicious insiders as primary vectors [1]. Based on established patterns in other technology sectors, the report identifies China as a potential source of increased IP targeting, though no neurotechnology-specific incidents are cited [1]. Military and higher education research laboratories are flagged as likely targets due to the proprietary research they hold [1].
Cyber exploitation and disruption of devices. Devices that process and transmit neural data introduce attack surfaces distinct from conventional IT hardware. Yale University researchers have identified specific risk categories for wireless BCIs, including unauthorized data interception and device output manipulation [10][11]. BCIs are classified as Class III medical devices (high risk), alongside pacemakers and cochlear implants, with average product lifetimes of 10 to 30 years [10]. Older legacy devices often have no method to upgrade software or patch bugs [10].
Data theft and extortion. Neurological and biometric datasets are candidates for exfiltration, extortion, and resale [2]. As neurotechnology moves into consumer wellness, gaming, and workplace applications, the volume of sensitive brain activity, biometric, and behavioral data collected by commercial platforms expands the attack surface significantly [2].
Legal and privacy risks. Neural data frequently lacks explicit legal protections in many jurisdictions, creating ambiguity that attackers can exploit and that victims may struggle to remedy [2]. The report notes that existing data and privacy protection laws will almost certainly need revision to address the emerging risks [2].
Alexander Leslie of Recorded Future stated: "Organisations operating in the neurotechnology field should establish rigorous continuous monitoring, vetting, and data access controls to counter industrial espionage and malicious insiders attempting to smuggle proprietary neurotech IP out of the organisation" [1]. Insikt Group also recommended that organizations "audit external manufacturing partners, hardware vendors, and subsidised software ecosystems (such as integrated wearable components) to prevent backdoor data access by foreign national security regimes" [1].
US-China Strategic Competition in Neurotechnology
The Insikt Group report frames neurotechnology as a focal point of strategic competition between the United States and China, analogous to the dynamic in artificial intelligence [2][3]. The US leads in the number of neurotechnology firms, and BCI research has been a long-term priority for the US military [3]. China's trajectory is distinct. Neuracle reportedly produced one of the first BCIs approved for commercial use [2]. In June 2026, China approved what is reported as the world's first commercial brain implant, allowing individuals with spinal cord injuries to regain motor control of their hands via a robotic glove [2].
China's central government issued a guiding document in July 2025 for developing BCI technology through 2030, and multiple provinces have issued dedicated plans [2]. State subsidies for major wearable technology firms and military research into human-machine integration indicate neurotechnology is a Chinese strategic priority [3]. The Insikt Group report assesses that China is likely to gain market share through affordable technology, potentially resulting in a larger global user base for Chinese neurotechnology products and greater data volumes flowing through Chinese-origin platforms [2].
A Fragmented US Regulatory Response
Four US states now classify brain data as sensitive personal information with specific legal protections: Colorado, California, Montana, and Connecticut [5][6]. Their approaches differ in ways that matter for compliance.
Colorado's amendment to the Colorado Privacy Act (HB 24-1058), effective since August 2024, is the narrowest. It treats neural data as "biological data" and applies protections only when the data is used for identification purposes [6]. California's SB 1223, effective January 2025, amended the California Consumer Privacy Act to cover information generated by measuring central or peripheral nervous system activity, but only when it is not inferred from non-neural sources [6]. Montana's SB 163, effective October 2025, takes a different path entirely, amending the state's Genetic Information Privacy Act and including a notable provision requiring law enforcement to obtain a search warrant before accessing neural data [6]. Connecticut's SB 1295 (signed June 2025, neural provisions effective July 1, 2026) covers only central nervous system activity, excluding peripheral signals, meaning it applies primarily to data collected from BCIs and EEG headsets [6][7].
The legislative momentum extends well beyond these four states. A March 2026 analysis by Morrison Foerster identified active neural data bills in Virginia, Alabama, California (a second measure), New York, Illinois, and Vermont [6]. Virginia's HB 654 classifies neural data as biometric data under existing consumer privacy law; Alabama's HB 263 creates a standalone neural data privacy statute; New York's S9008 would fold neural data into data broker regulations [6]. Illinois's HB 2984 proposes incorporating neural data into the state's existing Biometric Information Privacy Act (BIPA) framework [4]. Minnesota and Vermont have proposed neurotech-specific rules addressing brain-computer interfaces and "consciousness bypass" [4]. Several of these bills provide individuals with a private right of action for neural data violations [5].
At the federal level, US Senators introduced the MIND Act in late 2025, directing the FTC to study neural data privacy, but it has not advanced beyond committee [6]. Internationally, the UN, EU, and International Committee of the Red Cross have begun considering neurotechnology's human rights impacts [2]. The EU AI Act's guidelines explicitly reference brain-computer interfaces as a potential vector for manipulative techniques [6]. France and Germany are reportedly drafting laws to prohibit mandatory neurotechnology adoption in employment contracts [6].
FDA Cybersecurity Requirements for Neural Devices
The FDA published revised cybersecurity guidance for medical devices on February 3, 2026, superseding the prior version [8]. The guidance addresses requirements under Section 524B of the Federal Food, Drug, and Cosmetic Act for "cyber devices," defined as devices that include software, can connect to the internet, and have characteristics that could be vulnerable to cybersecurity threats [8][9].
Section 524B, which became effective March 29, 2023, requires manufacturers submitting marketing applications for cyber devices to include specific cybersecurity information in premarket submissions [8]. The FDA's 2026 guidance outlines five security objectives: authenticity, authorization, availability, confidentiality, and secure/timely updatability and patchability [8]. Manufacturers must implement a Secure Product Development Framework (SPDF) spanning design, development, release, support, and decommission phases, described by the FDA as "a set of processes that reduces the number and severity of vulnerabilities in products throughout the device lifecycle" [8].
Four types of testing are now required: security requirements testing, threat mitigation testing, proactive vulnerability hunting, and independent penetration testing by external parties [9]. Manufacturers must also produce a machine-readable Software Bill of Materials (SBOM) and maintain postmarket surveillance with Coordinated Vulnerability Disclosure processes [9]. The guidance aligns with the revised Quality Management System Regulation incorporating ISO 13485 by reference, effective February 2, 2026 [8].
This matters for BCIs specifically because they are classified as Class III medical devices with average product lifetimes of 10 to 30 years [10]. The Protecting and Transforming Cyber Health Care Act of 2022 (PATCH Act), enacted as part of the Food and Drug Omnibus Reform Act of 2022 (FDORA) within the Consolidated Appropriations Act, 2023, introduced the enforcement mechanisms requiring cybersecurity information alongside marketing applications [10]. Prior to 2022, cybersecurity guidelines for medical devices were only non-binding recommendations [10].
BCI Attack Surface Assessment
A Yale University research paper (Schroder et al.) published in 2025 provides a technical threat model for next-generation BCIs [10]. The researchers find that BCIs are at less risk of physical compromise but are vulnerable to remote attack via network paths [10]. Wireless BCIs present the most salient risk vectors: unauthorized data interception, device output manipulation, and compromise of communication protocols [10][11].
The FDA has previously warned patients and manufacturers of vulnerabilities in device communication protocols, such as the URGENT/11 family of vulnerabilities [10]. The theoretical risk from wireless BCIs is described as credible but not yet a documented pattern of real-world harm [11]. As of 2026, no confirmed cyberattack on a clinical BCI implant has been publicly reported [11].
The researchers recommend that regulators mandate non-surgical device update methods, strong authentication and authorization schemes for BCI software modifications, encryption of data moving to and from the brain, and minimized network connectivity where possible [10].
Analysis
The Insikt Group report fills a gap in the threat intelligence picture. Most cybersecurity analysis of medical devices focuses on well-established categories: infusion pumps, imaging systems, hospital networks. BCIs occupy a different position. They collect data that is fundamentally more sensitive than other biometric categories because neural signals can reveal cognitive and emotional states, not just identity markers [4][7]. The data has value for intelligence services, for criminal extortion, and for competitive advantage in an industry that the US and China both treat as strategically important.
The regulatory environment is advancing at different speeds across jurisdictions. Four US states have enacted protections with meaningful differences in scope and enforcement mechanisms. The private right of action provisions in some state bills (Illinois, Vermont) could create BIPA-style litigation exposure for companies collecting neural data [5]. The FDA's 2026 guidance closes some device-level gaps, particularly around SBOMs and mandatory penetration testing, but the guidance applies to devices seeking market authorization. Legacy BCIs already implanted in patients may not benefit from these requirements [10].
China's approval of what is reported as the first commercial brain implant and its five-year BCI development guidance signal that the supply chain for neurotechnology components will likely involve Chinese manufacturers. The Insikt Group's recommendation to audit external manufacturing partners and hardware vendors is directed at this specific risk [1].
Red Sheep Assessment
Confidence: Moderate
The sources collectively point to a gap between threat attention and threat realization. No confirmed attack has occurred, but the conditions that precede exploitation of new technology categories are present: rapid commercial adoption outpacing regulation, high-value data being collected by devices with long lifecycles and limited update mechanisms, and strategic competition creating incentives for both IP theft and supply chain compromise.
The most probable near-term threat vector is not exploitation of an implanted BCI. It is the exfiltration of neural datasets from commercial platforms and research institutions. Consumer EEG devices are already collecting neural data at scale with varying levels of security maturity [4][7]. These companies and the cloud infrastructure storing their data are softer targets than clinical implants, and the data they hold is becoming legally sensitive under multiple state regimes.
An alternative interpretation: the regulatory fragmentation itself becomes the primary risk multiplier. Companies operating across multiple US states face a patchwork of definitions (central nervous system only vs. peripheral signals included), consent requirements, and enforcement mechanisms that may divert security resources toward compliance overhead rather than actual security improvements. The BIPA-style private right of action in pending bills could produce a litigation environment that chills neurotechnology development in some states while pushing it to less regulated jurisdictions.
The Insikt Group's framing of China as the primary IP-theft threat source is consistent with established patterns in other technology sectors, but the report does not cite specific incidents involving neurotechnology companies. The assessment is pattern-based rather than evidence-based. Organizations should plan for a broader set of threat actors, including financially motivated groups targeting neural data for extortion once legal classifications make that data demonstrably sensitive and valuable.
Defender's Checklist
- ▢[ ] Inventory all neurotechnology devices and platforms collecting neural or biometric data in your environment, including consumer wellness devices used in research or employee programs. Use network asset discovery tools (e.g., Forescout eyeSight, Armis Centrix, or Nmap with service detection flags
-sV -O) to identify connected neurotechnology devices. Cross-reference against the FDA product classification database (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm) for Class III medical device designations. Maintain inventory in a CMDB with fields for firmware version, last patch date, and network connectivity type. - ▢[ ] Audit third-party manufacturers, hardware vendors, and software supply chains for BCI and neural data processing systems, following Insikt Group's recommendation to assess backdoor data access risks from foreign national security regimes [1]. Request and review SBOMs from all vendors in CycloneDX or SPDX format. Assess country-of-origin risks for firmware and hardware components against the ICTS (Information and Communications Technology and Services) supply chain rule maintained by the US Department of Commerce.
- ▢[ ] Review compliance obligations against enacted neural data privacy statutes: Colorado HB 24-1058, California SB 1223, Montana SB 163, and Connecticut SB 1295. Monitor pending legislation in Virginia (HB 654), Alabama (HB 263), New York (S9008), Illinois (HB 2984), Vermont, and Minnesota for enforcement timelines [5][6]. Map each statute's scope (CNS-only vs. peripheral signals, identification-only vs. all processing) to your organization's data collection practices.
- ▢[ ] Verify that any FDA-regulated cyber devices in your environment have current machine-readable SBOMs, have undergone independent penetration testing by qualified external parties, and have documented Coordinated Vulnerability Disclosure processes per the February 2026 FDA guidance [8][9]. For legacy implanted BCIs that predate the 2023 Section 524B requirements, document compensating controls (network segmentation, monitoring) and assess feasibility of firmware updates.
- ▢[ ] Implement role-based access controls (RBAC) with principle of least privilege for neural data repositories. Deploy DLP rules to detect bulk export of neural and biometric datasets (e.g., in Microsoft Purview, create custom sensitive information types for common neural data file formats such as EDF, BDF, and GDF; in Symantec DLP, configure fingerprinting policies against neural data stores). Configure SIEM alerts for anomalous access patterns to neural data stores: set threshold alerts for access to >100 records in a 10-minute window, create geofencing rules to alert on access from unexpected regions, monitor for off-hours access (define baseline per team), and flag bulk download events exceeding 50MB from neural data repositories. Review access logs quarterly.
References
[1] https://www.intelligentcio.com/me/2026/09/03/recorded-future-researchers-warn-neurotechnology-growth-could-create-new-targets-for-cybercriminals-and-state-backed-attackers/
[2] https://smbtech.au/news/brain-data-emerging-as-target-for-cybercriminals-and-state-linked-actors-as-neurotechnology-expands-beyond-clinical-use/
[3] https://mysecuritymarketplace.com/reports/emerging-threats-to-neurotechnology/
[4] https://www.rmmagazine.com/articles/article/2026/02/24/state-of-mind--the-new-landscape-of-neural-data-privacy-laws
[5] https://www.cooley.com/news/insight/2026/2026-02-23-your-brain-their-rules-the-growing-patchwork-of-neural-data-regulation
[6] https://insidebci.com/policy/2026-04-03-us-states-build-patchwork-of-neural-data-privacy-laws-as-bci-market-accelerates/
[7] https://bassberry.com/news/you-read-my-mind-neural-data-and-the-new-wave-of-biometric-privacy-protections/
[8] https://24x7mag.com/standards/safety/cybersecurity/fda-updates-medical-device-cybersecurity-guidance-address-new-federal-requirements/
[9] https://censinet.com/perspectives/fda-cybersecurity-guidance-medical-device-reporting-rules
[10] https://arxiv.org/pdf/2508.12571
[11] https://www.neuroba.com/post/brain-computer-interface-risks-what-the-science-actually-says